Get the Stockscreener App
766.66
3.05%
-24.15
After Hours:
769.67
3.01
+0.39%
Regeneron Pharmaceuticals Inc stock is traded at $766.66, with a volume of 636.85K.
It is down -3.05% in the last 24 hours and up +0.99% over the past month.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$790.81
Open:
$781.01
24h Volume:
636.85K
Relative Volume:
0.76
Market Cap:
$81.05B
Revenue:
$14.34B
Net Income/Loss:
$4.50B
P/E Ratio:
18.45
EPS:
41.5626
Net Cash Flow:
$3.77B
1W Performance:
-0.72%
1M Performance:
+0.99%
6M Performance:
+35.98%
1Y Performance:
+11.94%
1-Day Range:
$764.49
$794.77
1-Week Range:
$753.79
$794.77
52-Week Range:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Name
Regeneron Pharmaceuticals Inc
Sector
Industry
Phone
(914) 847-7000
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-03-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-24-25 | Initiated | HSBC Securities | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-14-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jun-30-25 | Downgrade | Argus | Buy → Hold |
| May-30-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-14-25 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-05-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jan-16-25 | Downgrade | UBS | Buy → Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Sep-24-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-12-24 | Initiated | Bernstein | Outperform |
| Jan-12-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-03-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-21-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-21-23 | Reiterated | Oppenheimer | Perform |
| Jun-28-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-27-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-24-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-23-23 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jan-30-23 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-20-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-26-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Oct-17-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-09-22 | Upgrade | Jefferies | Underperform → Hold |
| Sep-09-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-25-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-06-22 | Initiated | Jefferies | Underperform |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jan-03-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Dec-15-21 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Dec-07-21 | Resumed | Cowen | Market Perform |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Resumed | BMO Capital Markets | Outperform |
| Nov-05-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-29-21 | Initiated | H.C. Wainwright | Buy |
| Jan-25-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-13-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Jan-08-21 | Upgrade | Citigroup | Neutral → Buy |
| Oct-05-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-20-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-09-20 | Upgrade | SunTrust | Hold → Buy |
| May-26-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-17-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Apr-08-20 | Initiated | The Benchmark Company | Hold |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-26-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-25-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-11-20 | Upgrade | Argus | Hold → Buy |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-16-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-13-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-12-19 | Initiated | SunTrust | Hold |
| Nov-07-19 | Upgrade | Citigroup | Neutral → Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
View All
Regeneron Pharmaceuticals Inc Stock (REGN) Latest News
Sanofi (SNY) extends Dupixent reach and advances sleeping sickness drug - Stock Titan
RBC Maint. REGN (Regeneron Pharmaceuticals, Inc.) at Sector Perform, PT $765 Mar 2026 - Meyka
Sanofi (SNY) and Regeneron’s Dupixent Recommended for EU Approval - Yahoo! Finance Canada
RBC Capital Raises Price Target for REGN While Maintaining Ratin - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $765.00 at Royal Bank Of Canada - MarketBeat
Paroxysmal Nocturnal Hemoglobinuria Market: Expanding Revenue Landscape to 2034 – DelveInsight | Alexion Pharma, Hoffmann-La Roche, Novartis, Regeneron Pharma, AKARI Therapeutics, AstraZeneca - Barchart.com
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria - Yahoo Finance
RBC Raises Price Target on Regeneron Pharmaceuticals to $765 From $745, Keeps Sector Perform Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Evaluating the 11.3% Upside Potential - DirectorsTalk Interviews
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Regeneron Pharma Stock: Why Wall Street Is Watching This Biotech Rocket - AD HOC NEWS
Regeneron News Highlights Rare Disease Focus And Valuation Gap - simplywall.st
Regeneron’s Dupixent Win And Rare Disease Push Reshape Risk Reward Profile - Yahoo Finance
Rafferty Asset Management LLC Sells 6,156 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cache Advisors LLC - MarketBeat
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
Harvest Portfolios Group Inc. Has $60.47 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Handelsbanken Fonder AB Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by American Century Companies Inc. - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Raised to "Buy" at Wall Street Zen - MarketBeat
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds - Yahoo Finance
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - WebWire
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? - Barchart.com
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expa - GuruFocus
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - TradingView
Sarcopenia Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Oncocross, Biophytis, MyMD Pharmaceuticals, Novartis, Regeneron Pharma, Merck - StreetInsider
Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - The Manila Times
Mitsubishi UFJ Asset Management Co. Ltd. Has $121.55 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Erste Asset Management GmbH Sells 4,661 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Banco Santander S.A. - MarketBeat
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Dupixent’s New FDA Approval For Allergic Fungal Rhinosinusitis - simplywall.st
Regeneron Renews Sponsorship of the Regeneron Science Talent Sear - The National Law Review
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
K.J. Harrison & Partners Inc Has $2.46 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Dana Investment Advisors Inc. Buys Shares of 5,313 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children - Pharmaceutical Executive
Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036 - GlobeNewswire Inc.
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by TD Asset Management Inc - MarketBeat
FDA approves Dupixent as first treatment for AFRS - The Pharma Letter
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years - The Globe and Mail
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Cooling - Yahoo Finance
Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors? - Yahoo Finance
Is Dupixent’s First AFRS Approval Altering The Investment Case For Regeneron Pharmaceuticals (REGN)? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis - WebWire
FDA Approves Regeneron's (REGN) Dupixent for Allergic Fungal Rhi - GuruFocus
Regeneron Pharmaceuticals, Sanofi Secure FDA Approval for Dupixent Sinus Treatment - marketscreener.com
Sanofi, Regeneron's Allergic Fungal Rhinosinusitis Treatment Gets US FDA Clearance - marketscreener.com
Sanofi and Regeneron's Dupixent approved in the U.S. for Allergic Fungal Rhinosinusitis - marketscreener.com
Regeneron Pharmaceuticals gains FDA approval for allergy treatment - Traders Union
Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.06%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):